Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung c
- 1 November 1994
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 5 (9) , 852-853
- https://doi.org/10.1093/oxfordjournals.annonc.a059018
Abstract
B. Lund, M. Ryberg, P. Meidahl Petersen, H. Anderson, N. Thatcher, P. Dombernowsky; Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twicThis publication has 3 references indexed in Scilit:
- Treatment of non-small cell lung cancer: new cytostatic agentsLung Cancer, 1993
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Phase II study of gemcitabine in non small cell lung cancer (NSCLC): B. Lund, H. Anderson, J. Walling, N. Thatcher, H.H.Hansen Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark, and Wythenshawe Hospital, Manchester, EnglandLung Cancer, 1991